What 250+ People Report About Semaglutide — Self-Reported Community Data
Semaglutide is a GLP-1 receptor agonist approved by the FDA as Ozempic (type 2 diabetes) and Wegovy (weight management). Based on 250+ self-reported experience logs on Narrated, it is most commonly logged for fat loss (71%) and metabolic health (16%). The median self-reported outcome score at week 12 is 7.8/10. Compounded semaglutide is NOT FDA-approved and the FDA has issued specific warnings about compounded versions.
What is semaglutide?
Semaglutide is a glucagon-like intervention-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It works by mimicking the GLP-1 hormone, which regulates blood sugar, slows gastric emptying, and reduces appetite. It is available in branded injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations.
What is the regulatory status of semaglutide?
As of March 2026:
- FDA-approved: Yes — as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral, type 2 diabetes)
- Compounded semaglutide: NOT FDA-approved. The FDA has issued warnings about compounded versions, citing quality and safety concerns
- United Kingdom: Available via NHS and private prescription for approved indications
- Insurance: Coverage varies significantly by plan and indication
Important distinction: FDA-approved branded semaglutide and compounded semaglutide are not the same product. Compounded versions are produced by compounding pharmacies and do not undergo the same regulatory review.
What do people report when using semaglutide?
Based on 250+ self-reported experience logs on Narrated:
| Most common reported goal | Fat loss (71%) |
|---|---|
| Second most common goal | Metabolic health (16%) |
| Third most common goal | Appetite regulation (9%) |
| Median outcome score (week 12) | 7.8 / 10 |
| Would run again | 81% |
| Neutral | 14% |
| Would not run again | 5% |
Most commonly reported starting protocol: 0.25mg/week subcutaneous injection, titrating up over 4-8 weeks. Typical reported cycle length: 12-24 weeks.
What are the reported side effects of semaglutide?
From 250+ self-reported logs:
| Nausea (first 2-4 weeks) | 47% |
|---|---|
| Reduced appetite | 38% |
| None beyond appetite change | 22% |
| Fatigue | 14% |
| Constipation | 12% |
| Injection site reaction | 6% |
Note: Multiple side effects can be reported per log. Nausea is the most commonly reported side effect and typically resolves within the first month according to self-reports.
Is this medical advice?
No. Narrated aggregates self-reported community data. We do not recommend, rank, or advise the use of any compound. Always consult a healthcare professional.